334 related articles for article (PubMed ID: 35217809)
21. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
Carino A; Biagioli M; Marchianò S; Fiorucci C; Zampella A; Monti MC; Scarpelli P; Ricci P; Distrutti E; Fiorucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1422-1437. PubMed ID: 31325638
[TBL] [Abstract][Full Text] [Related]
22. Farnesoid X receptor modulators (2011 - 2014): a patent review.
Sepe V; Distrutti E; Fiorucci S; Zampella A
Expert Opin Ther Pat; 2015; 25(8):885-96. PubMed ID: 26183029
[TBL] [Abstract][Full Text] [Related]
23. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.
Jung H; Chen J; Hu X; Sun H; Wu SY; Chiang CM; Kemper B; Chen LF; Kemper JK
JCI Insight; 2020 Dec; 6(1):. PubMed ID: 33290278
[TBL] [Abstract][Full Text] [Related]
24. Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice.
Liu SY; Huang CC; Yang YY; Huang SF; Lee TY; Li TH; Hou MC; Lin HC
PLoS One; 2022; 17(12):e0276717. PubMed ID: 36490253
[TBL] [Abstract][Full Text] [Related]
25. Recent Advances in the Medicinal Chemistry of Farnesoid X Receptor.
Fang Y; Hegazy L; Finck BN; Elgendy B
J Med Chem; 2021 Dec; 64(24):17545-17571. PubMed ID: 34889100
[TBL] [Abstract][Full Text] [Related]
26. Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis.
Venetsanaki V; Karabouta Z; Polyzos SA
Eur J Pharmacol; 2019 Nov; 863():172661. PubMed ID: 31536725
[TBL] [Abstract][Full Text] [Related]
27. Discovery of HPG1860, a Structurally Novel Nonbile Acid FXR Agonist Currently in Clinical Development for the Treatment of Nonalcoholic Steatohepatitis.
Mo C; Xu X; Zhang P; Peng Y; Zhao X; Chen S; Guo F; Xiong Y; Chu XJ; Xu X
J Med Chem; 2023 Jul; 66(14):9363-9375. PubMed ID: 37424079
[TBL] [Abstract][Full Text] [Related]
28. FXR and NASH: an avenue for tissue-specific regulation.
Henry Z; Meadows V; Guo GL
Hepatol Commun; 2023 May; 7(5):. PubMed ID: 37058105
[TBL] [Abstract][Full Text] [Related]
29. Discovery of 4-aminophenylacetamide derivatives as intestine-specific farnesoid X receptor antagonists for the potential treatment of nonalcoholic steatohepatitis.
Chen C; Zhang B; Tu J; Peng Y; Zhou Y; Yang X; Yu Q; Tan X
Eur J Med Chem; 2024 Jan; 264():115992. PubMed ID: 38043493
[TBL] [Abstract][Full Text] [Related]
30. Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis.
Schumacher JD; Guo GL
Handb Exp Pharmacol; 2019; 256():325-357. PubMed ID: 31201553
[TBL] [Abstract][Full Text] [Related]
31. Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis.
Chianelli D; Rucker PV; Roland J; Tully DC; Nelson J; Liu X; Bursulaya B; Hernandez ED; Wu J; Prashad M; Schlama T; Liu Y; Chu A; Schmeits J; Huang DJ; Hill R; Bao D; Zoll J; Kim Y; Groessl T; McNamara P; Liu B; Richmond W; Sancho-Martinez I; Phimister A; Seidel HM; Badman MK; Joseph SB; Laffitte B; Molteni V
J Med Chem; 2020 Apr; 63(8):3868-3880. PubMed ID: 31940200
[TBL] [Abstract][Full Text] [Related]
32. Discovery of LH10, a novel fexaramine-based FXR agonist for the treatment of liver disease.
Huang W; Cao Z; Wang W; Yang Z; Jiao S; Chen Y; Chen S; Zhang L; Li Z
Bioorg Chem; 2024 Feb; 143():107071. PubMed ID: 38199141
[TBL] [Abstract][Full Text] [Related]
33. Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders.
Fiorucci S; Di Giorgio C; Distrutti E
Handb Exp Pharmacol; 2019; 256():283-295. PubMed ID: 31201552
[TBL] [Abstract][Full Text] [Related]
34. Progress and challenges of selective Farnesoid X Receptor modulation.
Massafra V; Pellicciari R; Gioiello A; van Mil SWC
Pharmacol Ther; 2018 Nov; 191():162-177. PubMed ID: 29933033
[TBL] [Abstract][Full Text] [Related]
35. Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists.
Shah RA; Alkhouri N; Kowdley KV
Expert Opin Emerg Drugs; 2020 Sep; 25(3):251-260. PubMed ID: 32686578
[TBL] [Abstract][Full Text] [Related]
36. Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease.
Abenavoli L; Falalyeyeva T; Boccuto L; Tsyryuk O; Kobyliak N
Pharmaceuticals (Basel); 2018 Oct; 11(4):. PubMed ID: 30314377
[TBL] [Abstract][Full Text] [Related]
37. Obeticholic acid inhibits hepatic fatty acid uptake independent of FXR in mouse.
Lin C; Yu B; Liu X; Chen L; Zhang Z; Ye W; Zhong H; Bai W; Yang Y; Nie B
Biomed Pharmacother; 2022 Jun; 150():112984. PubMed ID: 35447541
[TBL] [Abstract][Full Text] [Related]
38. Update on FXR Biology: Promising Therapeutic Target?
Han CY
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30013008
[TBL] [Abstract][Full Text] [Related]
39. INT-767 improves histopathological features in a diet-induced
Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
[TBL] [Abstract][Full Text] [Related]
40. Patented Farnesoid X receptor modulators: a review (2019 - present).
Gioiello A; Rosatelli E; Cerra B
Expert Opin Ther Pat; 2024 Jul; 34(7):547-564. PubMed ID: 38308658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
